Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing

This article has no abstract
Epistemonikos ID: 23b0cf88fd5b95f4e764355ff40c6cbd4f203a6f
First added on: Feb 09, 2025